{"title":"Systematic review of retinal toxicity after injection of cefuroxime during cataract surgery.","authors":"Shan-Shan Wang, Bi-Jun Zhu, Jian-Nan Huang, Bao-Jiang Li, Ying-Yan Ma, Hai-Dong Zou","doi":"10.18240/ijo.2025.10.24","DOIUrl":null,"url":null,"abstract":"<p><p>This review is to elucidate the retinal toxicity following intraocular injections of cefuroxime, including possible risk factors, clinical manifestations, visual prognosis and treatment. Refereed publications were retrieved from PubMed, the Cochrane Library, and EMBASE databases, using the search terms cefuroxime, retina, macular edema, serous retinal detachment, toxic, cataract surgery. The screening was not limited by publication date, country or study type. We screened out 51 articles out of which 32 met the inclusion criteria for this systematic review. Data regarding sample size calculation reporting and trial characteristics were extracted for each trial. Retinal toxicity can be caused by both high and standard doses of cefuroxime injections in different ethnic groups, with risk factors including overdose, blood-retinal barrier disruption, anterior and posterior chamber connection. The typical clinical manifestations of retinal toxicity are cystoid macular edema and extensive serous retinal detachment, mainly involving the outer nuclear and outer plexiform layers, with a good prognosis for visual acuity in most cases, but in a small number of cases, the prognosis is not satisfactory. In conclusion, though the current use of intracameral injection antibiotics in cataract surgery is gradually increasing, the potential risks should not be ignored. Unexplained poor vision on the first day after cataract surgery can be supplemented with macular optical coherence tomography to rule out cefuroxime-related retinal toxicity.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 10","pages":"1990-1999"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454015/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.10.24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This review is to elucidate the retinal toxicity following intraocular injections of cefuroxime, including possible risk factors, clinical manifestations, visual prognosis and treatment. Refereed publications were retrieved from PubMed, the Cochrane Library, and EMBASE databases, using the search terms cefuroxime, retina, macular edema, serous retinal detachment, toxic, cataract surgery. The screening was not limited by publication date, country or study type. We screened out 51 articles out of which 32 met the inclusion criteria for this systematic review. Data regarding sample size calculation reporting and trial characteristics were extracted for each trial. Retinal toxicity can be caused by both high and standard doses of cefuroxime injections in different ethnic groups, with risk factors including overdose, blood-retinal barrier disruption, anterior and posterior chamber connection. The typical clinical manifestations of retinal toxicity are cystoid macular edema and extensive serous retinal detachment, mainly involving the outer nuclear and outer plexiform layers, with a good prognosis for visual acuity in most cases, but in a small number of cases, the prognosis is not satisfactory. In conclusion, though the current use of intracameral injection antibiotics in cataract surgery is gradually increasing, the potential risks should not be ignored. Unexplained poor vision on the first day after cataract surgery can be supplemented with macular optical coherence tomography to rule out cefuroxime-related retinal toxicity.
期刊介绍:
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.